FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4296480811> ?p ?o ?g. }

• W4296480811 endingPage "580" @default.
• W4296480811 startingPage "572" @default.
• W4296480811 abstract "To evaluate the pathological complete response (pCR) rate of locally advanced rectal cancer (LARC) after adaptive high-dose neoadjuvant chemoradiation (CRT) based on 18 F-fluorodeoxyglucose positron emission tomography/computed tomography (18 F-FDG-PET/CT).The primary endpoint was the pCR rate. Secondary endpoints were the predictive value of 18 F-FDG-PET/CT on pathological response and acute and late toxicity. All patients performed 18 F-FDG-PET/CT at baseline (PET0) and after 2 weeks during CRT (PET1). The metabolic PET parameters were calculated both at the PET0 and PET1. The total CRT dose was 45 Gy to the pelvic lymph nodes and 50 Gy to the primary tumor, corresponding mesorectum, and to metastatic lymph nodes. Furthermore, a sequential boost was delivered to a biological target volume defined by PET1 with an additional dose of 5 Gy in 2 fractions. Capecitabine (825 mg/m2 twice daily orally) was prescribed for the entire treatment duration.Eighteen patients (13 males, 5 females; median age 55 years [range, 41-77 years]) were enrolled in the trial. Patients underwent surgical resection at 8-9 weeks after the end of neoadjuvant CRT. No patient showed grade > 1 acute radiation-induced toxicity. Seven patients (38.8%) had TRG = 0 (complete regression), 5 (27.0%) showed TRG = 2, and 6 (33.0%) had TRG = 3. Based on the TRG results, patients were classified in two groups: TRG = 0 (pCR) and TRG = 1, 2, 3 (non pCR). Accepting p < 0.05 as the level of significance, at the Kruskal-Wallis test, the medians of baseline-MTV, interim-SUVmax, interim-SUVmean, interim-MTV, interim-TLG, and the MTV reduction were significantly different between the two groups. 18 F-FDG-PET/CT was able to predict the pCR in 77.8% of cases through compared evaluation of both baseline PET/CT and interim PET/CT.Our results showed that a dose escalation on a reduced target in the final phase of CRT is well tolerated and able to provide a high pCR rate." @default.
• W4296480811 created "2022-09-21" @default.
• W4296480811 creator A5000531166 @default.
• W4296480811 creator A5016317626 @default.
• W4296480811 creator A5017414279 @default.
• W4296480811 creator A5021554584 @default.
• W4296480811 creator A5023581542 @default.
• W4296480811 creator A5030819607 @default.
• W4296480811 creator A5032386417 @default.
• W4296480811 creator A5032777467 @default.
• W4296480811 creator A5033149100 @default.
• W4296480811 creator A5033505744 @default.
• W4296480811 creator A5060396380 @default.
• W4296480811 creator A5070057686 @default.
• W4296480811 creator A5070096760 @default.
• W4296480811 creator A5074512572 @default.
• W4296480811 creator A5074927059 @default.
• W4296480811 creator A5076625264 @default.
• W4296480811 creator A5089554789 @default.
• W4296480811 creator A5090863427 @default.
• W4296480811 creator A5090966339 @default.
• W4296480811 date "2022-09-21" @default.
• W4296480811 modified "2023-09-30" @default.
• W4296480811 title "Adaptive Individualized high-dose preoperAtive (AIDA) chemoradiation in high-risk rectal cancer: a phase II trial" @default.
• W4296480811 cites W152901929 @default.
• W4296480811 cites W1602443498 @default.
• W4296480811 cites W1963653242 @default.
• W4296480811 cites W1971080739 @default.
• W4296480811 cites W1973249355 @default.
• W4296480811 cites W2029409133 @default.
• W4296480811 cites W2031996887 @default.
• W4296480811 cites W2038206658 @default.
• W4296480811 cites W2041282815 @default.
• W4296480811 cites W2057673013 @default.
• W4296480811 cites W2060653243 @default.
• W4296480811 cites W2065969200 @default.
• W4296480811 cites W2071038583 @default.
• W4296480811 cites W2073631512 @default.
• W4296480811 cites W2085188388 @default.
• W4296480811 cites W2102583333 @default.
• W4296480811 cites W2102724015 @default.
• W4296480811 cites W2124556934 @default.
• W4296480811 cites W2136732497 @default.
• W4296480811 cites W2144717403 @default.
• W4296480811 cites W2154026393 @default.
• W4296480811 cites W2160655529 @default.
• W4296480811 cites W2161581516 @default.
• W4296480811 cites W2162098151 @default.
• W4296480811 cites W2170857061 @default.
• W4296480811 cites W2262931351 @default.
• W4296480811 cites W2413331746 @default.
• W4296480811 cites W2464549554 @default.
• W4296480811 cites W2485009944 @default.
• W4296480811 cites W2520102805 @default.
• W4296480811 cites W2751497722 @default.
• W4296480811 cites W2887321790 @default.
• W4296480811 cites W2895926103 @default.
• W4296480811 cites W2902561775 @default.
• W4296480811 cites W2911862581 @default.
• W4296480811 cites W4200338789 @default.
• W4296480811 cites W4200530694 @default.
• W4296480811 cites W4232052122 @default.
• W4296480811 cites W4247881463 @default.
• W4296480811 doi "https://doi.org/10.1007/s00259-022-05944-0" @default.
• W4296480811 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36127416" @default.
• W4296480811 hasPublicationYear "2022" @default.
• W4296480811 type Work @default.
• W4296480811 citedByCount "0" @default.
• W4296480811 crossrefType "journal-article" @default.
• W4296480811 hasAuthorship W4296480811A5000531166 @default.
• W4296480811 hasAuthorship W4296480811A5016317626 @default.
• W4296480811 hasAuthorship W4296480811A5017414279 @default.
• W4296480811 hasAuthorship W4296480811A5021554584 @default.
• W4296480811 hasAuthorship W4296480811A5023581542 @default.
• W4296480811 hasAuthorship W4296480811A5030819607 @default.
• W4296480811 hasAuthorship W4296480811A5032386417 @default.
• W4296480811 hasAuthorship W4296480811A5032777467 @default.
• W4296480811 hasAuthorship W4296480811A5033149100 @default.
• W4296480811 hasAuthorship W4296480811A5033505744 @default.
• W4296480811 hasAuthorship W4296480811A5060396380 @default.
• W4296480811 hasAuthorship W4296480811A5070057686 @default.
• W4296480811 hasAuthorship W4296480811A5070096760 @default.
• W4296480811 hasAuthorship W4296480811A5074512572 @default.
• W4296480811 hasAuthorship W4296480811A5074927059 @default.
• W4296480811 hasAuthorship W4296480811A5076625264 @default.
• W4296480811 hasAuthorship W4296480811A5089554789 @default.
• W4296480811 hasAuthorship W4296480811A5090863427 @default.
• W4296480811 hasAuthorship W4296480811A5090966339 @default.
• W4296480811 hasBestOaLocation W42964808111 @default.
• W4296480811 hasConcept C121608353 @default.
• W4296480811 hasConcept C126322002 @default.
• W4296480811 hasConcept C126838900 @default.
• W4296480811 hasConcept C199374082 @default.
• W4296480811 hasConcept C203092338 @default.
• W4296480811 hasConcept C2775842073 @default.
• W4296480811 hasConcept C2777909004 @default.
• W4296480811 hasConcept C2779013556 @default.
• W4296480811 hasConcept C2780283643 @default.

• next